Kodiak Sciences

Kodiak Sciences is a clinical stage biopharmaceutical company focusing on therapeutics to treat chronic, high-prevalence retinal diseases. The company's main product candidate is KSI-301, a biologic therapy built with the company's antibody biopolymer conjugate platform, which is designed to maintain drug levels in ocular tissues. KSI-301 is used to treat patients with wet age-related macular degeneration, diabetic retinopathy, including diabetic macular edema, and macular edema due to retinal vein occlusion. The company has applied its antibody biopolymer conjugate platform to develop additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate.
  • TickerKOD
  • ISINUS50015M1099
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Jonathan Moreland

InsiderInsights Daily Ratings Report: December 23, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Weekly Tables: November 28, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: November 24, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Jonathan Moreland

InsiderInsights Daily Ratings Report: December 23, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Weekly Tables: November 28, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: November 24, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch